Submission of Transcripts for the Earnings Call Held on August 10, 2026

AI summary - Q1 FY27 revenue 281cr +14% y-y; EBITDA 83cr +18%, margin 29.7% +120bps; PAT 48cr +17%, margin 17.1% +40bps - Healthcare revenue grew 85% to 142cr, largest segment; driven by pen injectors including GLP-1 and insulin - Consumer segment revenue declined 24% to 116cr due to softer demand in Europe and US - Industrial segment revenue up 25% to 23cr; new projects in Consumer Electronics and Automotive - Pen injector capacity to reach 75 million pens p.a. by Sept; 9 million pens done in Q1, 50-60% GLP-1 - New lines ramp-up ongoing; expect efficiency improvements and potential to exceed 36 million pens guidance - Emergency use, reusable, and on-body auto-injectors in development; reusable to launch by year-end - Capex: 5cr for Semiconductor Trays; 80-100cr for new Consumer Electronics plant - Domestic revenue share rising due to Healthcare and new segments; exports still majority - Management confident on scaling Healthcare business and expanding strategic partnerships in US and Europe